Medical-device maker Masimo makes a product that is “the gold standard” for the industry, Chairman and CEO Joe Kiani told Cramer Tuesday on Mad Money.

When it comes to pulse oximetry, or measuring the oxygen level in blood, Masimo’s

MASI loading...

Quote  |  Chart  |  News  |  Profile

[MASI  Loading...      ()   ] non-invasive fingertip sensor has been touted as the best by over 100 independent and objective studies, the CEO said.

And Masimo isn’t relying on just one product to fuel its growth either. Sure, pulse oximetry is a billion-dollar market, growing at 8% annually. But the analysts that cover the company say the market for all of Masimo’s products combined adds up to $2 billion to $3 billion.

Cramer likes the stock because subprime and a lagging economy can’t hurt it. He’s bullish on Masimo.

Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

Tools:

PrintEmail

Next Post

Previous PostBack to Main Page

• 

COMMENTS

More Comments

 

« First | « Previous

Next » | Last »

Thank you for joining our discussion. Your comment has been posted.

ADD COMMENTS

Please Sign In or Register to participate.

In order to add a comment you must click here and accept our terms and conditions.

Edit Screen Name

Please sign-in/optin or register to be able to submit comments.

Remaining characters

CNBC welcomes your contribution. Please respect our community and the integrity of its participants. CNBC reserves the right to moderate and approve your comment.

PREVIEW COMMENT

Your comments have not been posted yet.
Please review your submission to make sure you are comfortable with your entry.

Your Comments: